)
)
)
Sebastian BioPharma
Sebastian BioPharma is a preclinical oncology company developing tumor-targeted, multi-pathway therapeutics for colorectal cancer and other immunotherapy-resistant solid tumors. Our lead program uses a dual payload antibody–oligonucleotide conjugate approach designed to overcome tumor immune escape while reducing systemic toxicity, with expansion potential across additional solid tumors.
What is your next catalyst (value inflection) update?
Lead candidate nomination
Year Founded
2025
Lead Product in Development
SBP-001, a tumor-targeted dual payload antibody–oligonucleotide conjugate designed to overcome immune resistance in colorectal cancer
Development Phase of Lead Product
Discovery
Number of Unlicensed Products Looking for Licensing
1
CEO/Top Company Official
Greta Garrido
When you expect your next catalyst update?
Q4 2026 lead candidate nomination for SBP-001, establishing a clear inflection point ahead of IND-enabling studies.
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
